Ovarian Cancer – Current Treatment – Detailed, Expanded Analysis: Treatment Sequencing (US)
KEY BENEFITS AND USES
Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
Drill down into physicians’ treatment sequences and understand whom to position against or how to defend share.
Identify untapped treatment scenarios and key competitors to aid trial design.
Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
Discover untapped populations to expand product share and drive strategic decisions.
QUESTIONS ANSWERED
Where is my product positioned versus competitors in the treatment journey?
What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
What are the market-relevant treatment scenarios according to oncology experts?
Where are the untapped business opportunities on which I can capitalize?
How can I optimize trial design and ensure a competitive edge for my pipeline asset?
GEOGRAPHIES
United States
PRIMARY MARKET RESEARCH
Survey of 102 U.S. medical oncologists
PRODUCT DESCRIPTION
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts’ assumptions.
Ovarian Cancer - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)
Treatment sequencing ovarian cancer US May 2022 Updated
Tiffany Chan
Tiffany Chan, Ph.D., is an analyst on the Oncology team at Clarivate. Prior to joining Clarivate, she worked as a postdoctoral researcher at the University of Oxford, where her research focused on the high-throughput screening of 177Lu-PSMA combination therapies for the treatment of prostate cancer. She obtained her Ph.D. in chemistry from Imperial College London, which is affiliated with the Imperial Centre of Excellence in Neurotechnology and the Department of Biomedical Engineering.
